CN101214289B - 一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 - Google Patents
一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN101214289B CN101214289B CN2008100556375A CN200810055637A CN101214289B CN 101214289 B CN101214289 B CN 101214289B CN 2008100556375 A CN2008100556375 A CN 2008100556375A CN 200810055637 A CN200810055637 A CN 200810055637A CN 101214289 B CN101214289 B CN 101214289B
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- radix astragali
- herba
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010043561 Thrombocytopenic purpura Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 28
- 239000003814 drug Substances 0.000 claims abstract description 51
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 3
- 235000011477 liquorice Nutrition 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 239000009636 Huang Qi Substances 0.000 claims description 46
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 36
- 241000180649 Panax notoginseng Species 0.000 claims description 36
- 239000000706 filtrate Substances 0.000 claims description 33
- 108010052008 colla corii asini Proteins 0.000 claims description 32
- 238000001035 drying Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 17
- 230000006837 decompression Effects 0.000 claims description 14
- 238000004064 recycling Methods 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000007560 sedimentation technique Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 208000032843 Hemorrhage Diseases 0.000 abstract description 9
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 abstract description 9
- 238000001816 cooling Methods 0.000 abstract description 7
- 230000000740 bleeding effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 235000017060 Arachis glabrata Nutrition 0.000 abstract description 2
- 244000105624 Arachis hypogaea Species 0.000 abstract description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract description 2
- 235000018262 Arachis monticola Nutrition 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 235000020232 peanut Nutrition 0.000 abstract description 2
- 241000195974 Selaginella Species 0.000 abstract 3
- 239000008267 milk Substances 0.000 abstract 3
- 210000004080 milk Anatomy 0.000 abstract 3
- 235000013336 milk Nutrition 0.000 abstract 3
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 241001530884 Gynura segetum Species 0.000 abstract 1
- 244000017020 Ipomoea batatas Species 0.000 abstract 1
- 235000002678 Ipomoea batatas Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 240000005001 Paeonia suffruticosa Species 0.000 abstract 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 239000009685 tusanqi Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 210000001772 blood platelet Anatomy 0.000 description 19
- 229960004756 ethanol Drugs 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 8
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000023597 hemostasis Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 229940023488 pill Drugs 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001501 megacaryocyte Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000019838 Blood disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 206010037549 Purpura Diseases 0.000 description 3
- 241001672981 Purpura Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- -1 antiseptic Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 208000014951 hematologic disease Diseases 0.000 description 3
- 208000018706 hematopoietic system disease Diseases 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940085605 saccharin sodium Drugs 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010071229 Procedural haemorrhage Diseases 0.000 description 1
- 206010067354 Radiation leukopenia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 药物剂量(/kg) | 动物数(只) | BPC | 血小板增加 |
正常对照组 | ----- | 10 | 766.9±109.3 | ---- |
模型组 | ----- | 10 | 509.7±70.2 | -33.5% |
本发明小剂量组 | 12g | 10 | 712.9±208.1 | 1.7% |
本发明中剂量组 | 24g | 10 | 805.9±115.7* | 5.1% |
本发明大剂量组 | 36g | 10 | 869.4±125.9* | 5.9% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100556375A CN101214289B (zh) | 2008-01-04 | 2008-01-04 | 一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100556375A CN101214289B (zh) | 2008-01-04 | 2008-01-04 | 一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101214289A CN101214289A (zh) | 2008-07-09 |
CN101214289B true CN101214289B (zh) | 2011-05-04 |
Family
ID=39620837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100556375A Expired - Fee Related CN101214289B (zh) | 2008-01-04 | 2008-01-04 | 一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101214289B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657770B (zh) * | 2012-05-28 | 2013-07-03 | 石家庄平安医院有限公司 | 一种治疗特发性血小板减少性紫癜的药物组合物及其制备方法 |
CN102920836B (zh) * | 2012-11-28 | 2014-05-07 | 徐昌万 | 一种治疗免疫性血小板减少性紫癜的中药组合物 |
CN104258327A (zh) * | 2014-09-19 | 2015-01-07 | 河南福森药业有限公司 | 一种增强免疫力的保健颗粒剂及其制备方法 |
CN104491563A (zh) * | 2015-01-16 | 2015-04-08 | 王春燕 | 防治血小板减少性紫癜的中药制剂及其制备方法 |
CN105833014A (zh) * | 2016-05-23 | 2016-08-10 | 上海市青浦区中医医院 | 一种治疗血小板减少紫癜的中药组合物及其应用 |
-
2008
- 2008-01-04 CN CN2008100556375A patent/CN101214289B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101214289A (zh) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101095825A (zh) | 一种治疗乳腺增生、乳腺炎的中成药及其制备方法 | |
CN101199586B (zh) | 一种用于紫癜的药物 | |
CN101214289B (zh) | 一种用于治疗血小板减少性紫癜的中药组合物及其制备方法 | |
CN103386022B (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
CN102552517A (zh) | 妇科无糖型妇康宝颗粒剂及其制备方法 | |
CN106362104A (zh) | 一种治疗青春期多囊卵巢综合征的药物组合物 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN103735937A (zh) | 具有促进铁成分吸收并且补血的药物及保健品 | |
CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
CN100421699C (zh) | 一种治疗男性不育生精复方中药制剂 | |
CN103341013B (zh) | 一种治疗腰腿痛的中药 | |
CN101317958B (zh) | 治疗痛风的药物-痛风宁胶囊及其制备方法 | |
CN103585515A (zh) | 用于治疗儿童营养性贫血的泡腾剂药物 | |
CN104436121B (zh) | 一种治疗月经不调、小腹胀满、久不受孕的药物 | |
CN112773842A (zh) | 一种益肾健腰制剂及其制备方法 | |
CN106266204A (zh) | 一种治疗骨质疏松的药物 | |
CN101375955B (zh) | 一种用于治疗不射精症的通精制剂及其制备方法 | |
CN101843668A (zh) | 一种治疗股骨头坏死的中药颗粒剂及其制备方法 | |
CN110141656A (zh) | 一种妇科调经养血中药组合物及其制备方法 | |
CN109876127A (zh) | 一种养血当归胶囊及其制备方法 | |
CN104491762A (zh) | 一种治疗跌打损伤的药物组合及制备方法 | |
CN103638336A (zh) | 全天麻片 | |
CN1251723C (zh) | 治疗特发性血小板减少性紫癜血热病的药物组合物及制法 | |
CN103272029A (zh) | 一种治疗高血压的中药组方 | |
CN102423367B (zh) | 一种养颜活血药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160415 Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianshili Modern Chinese Medicine City, No. 2 East Road of Puji River, Beichen District, Tianjin Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190510 Address after: 215123 Unit 501C, C19 Floor, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province Patentee after: Suzhou Gongzheng Biomedical Technology Co.,Ltd. Address before: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20200104 |
|
CF01 | Termination of patent right due to non-payment of annual fee |